See the DrugPatentWatch profile for Zynlonta
What is Zynlonta, and what is it used for?
Zynlonta is a brand name for loncastuximab tesirine, an antibody-drug conjugate used to treat certain types of lymphoma. It is designed to deliver a chemotherapy-like payload to cancer cells that express the target antigen.
How does Zynlonta work (and what does “tesirine” mean)?
Zynlonta is an antibody-drug conjugate: it links an antibody (that targets a specific cell marker) with a cytotoxic drug payload. After the antibody binds to target cells, the conjugate is internalized and the payload is released inside the cell to trigger cell death.
What patients may be eligible to receive Zynlonta?
Eligibility depends on the exact lymphoma type and prior treatments, which are determined by the prescribing information and regional approvals. Zynlonta is typically used in relapsed or refractory settings for the lymphoma indications it is approved for.
What side effects are associated with Zynlonta?
Common and clinically important risks can include blood-count suppression and immune or infusion-related effects, along with other adverse events that occur with antibody-drug conjugates. The specific frequency and severity depend on the lymphoma regimen and patient factors, and clinicians rely on the full label for guidance.
How is Zynlonta given?
Zynlonta is administered by intravenous infusion, with dosing schedules set by the prescribing information and adjusted based on tolerability and treatment response.
Is Zynlonta affected by patents or exclusivity?
Patent and exclusivity status can change over time depending on filings and court rulings. For up-to-date patent intelligence (including related patents and potential expiration timelines), DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
How does Zynlonta compare with other lymphoma drugs?
Zynlonta is one option among targeted therapies and antibody-drug conjugates used in lymphoma. Comparisons depend on the specific lymphoma subtype, line of therapy (e.g., after prior chemotherapy or after immunotherapy), and patient factors such as prior exposure and performance status.
Quick check: what do you mean by “Zynlonta”?
People ask different things when they search this name. If you tell me what you want—uses/indication, dosing schedule, side effects, cost, or patent/exclusivity—I can focus the answer accordingly.